Mabion S.A.

Mabion S.A. (WSE: MAB), is Polish biopharmaceutical company established in 2007 with its core competency being the development of latest generation pharmaceuticals based on recombinant proteins technologies (e.g. monoclonal antibodies). Mabion’s capabilities begin with the drug design phase, including selection of both upstream and downstream technologies, up through GMP manufacturing operations (DS and DP), as well as development of analytical tools (structural, functional, physicochemical), clinical development, clinical analytics (PK, PD, NAB, ADA) and full regulatory coverage of all development and operational activities. The company’s most advanced project is MabionCD20, a biosimilar to MabThera (Rituximab) with the therapeutic indications for non-Hodgkin’s lymphoma, Leukemia and Rheumatoid Arthritis (RA). Currently, MabionCD20 is in an advanced clinical stage. Since signing a contract with Novavax in October 2021 for the commercial production of a COVID-19 vaccine, Mabion has been developing and extending its existing platform to CDMO activities, namely contract development, GMP manufacturing services, and GMP/GLP analytical services in the full scope of the capabilities mentioned above. Mabion has been listed on the Warsaw Stock Exchange since 2013.